MANNKIND CORP Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
MANNKIND CORP (MNKD) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $100.00 thousand as of 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2023-11-07
- 2023-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $100.00K.
- 2023-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $100.00K.
- 2023-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $100.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2023-09-30 | $100.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | $100.00K 10-Q · filed 2023-08-07 |
| 2023-03-31 | $100.00K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |